# Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

> **NCT01235598** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 41 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Certolizumab Pegol (CZP) 200 mg
- **BIOLOGICAL:** Certolizumab Pegol (CZP) 400 mg

## Key facts

- **NCT ID:** NCT01235598
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-09
- **Final completion:** 2013-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235598, "Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01235598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*